Oncoproteomic analysis reveals co-upregulation of RELA and STAT5 in carboplatin resistant ovarian carcinoma.

Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: Electronic Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE

Original Publication: San Francisco, CA : Public Library of Science

Proteomics* ; Up-Regulation*; Antineoplastic Agents/*therapeutic use ; Carboplatin/*therapeutic use ; Neoplasm Proteins/*metabolism ; Ovarian Neoplasms/*metabolism ; STAT5 Transcription Factor/*metabolism ; Transcription Factor RelA/*metabolism; Apoptosis ; Chromatin Immunoprecipitation ; Drug Resistance, Neoplasm ; Enzyme-Linked Immunosorbent Assay ; Female ; Humans ; Ovarian Neoplasms/drug therapy ; Ovarian Neoplasms/pathology ; STAT5 Transcription Factor/genetics ; Spectrometry, Mass, Electrospray Ionization ; Tandem Mass Spectrometry ; Transcription Factor RelA/genetics

Background: Ovarian cancer is one of the most lethal types of female malignancy. Although most patients are initially responsive to platinum-based chemotherapy, almost all develop recurrent chemoresistant tumors and succumb to their diseases. Elucidating the pathogenesis underlying drug resistance is fundamental to the development of new therapeutics, leading to improved clinical outcomes in these patients.
Methods and Findings: We compared the proteomes of paired primary and recurrent post-chemotherapy ovarian high-grade serous carcinomas from nine ovarian cancer patients using CIEF/Nano-RPLC coupled with ESI-Tandem MS. As compared to their primary tumors, more than half of the recurrent tumors expressed higher levels of several proteins including CP, FN1, SYK, CD97, AIF1, WNK1, SERPINA3, APOD, URP2, STAT5B and RELA (NF-kappaB p65), which were also validated by quantitative RT-PCR. Based on shRNA screening for the upregulated genes in in vitro carboplatin-resistant cells, we found that simultaneous knockdown of RELA and STAT5B was most effective in sensitizing tumor cells for carboplatin treatment. Similarly, the NF-kappaB inhibitor, BMS-345541, and the STAT5 inhibitor, Dasatinib, significantly enhanced cell sensitivity to carboplatin. Moreover, both RELA and STAT5 are known to bind to the promoter region of Bcl-X, regulating its promoter activity. In this regard, augmented Bcl-xL expression was detected in carboplatin-resistant cells. Combined ectopic expression of RELA and STAT5B enhanced Bcl-xL promoter activity while treatment with BMS-345541 and Dasatinib decreased it. Chromatin immunoprecipitation of the Bcl-X promoter region using a STAT5 antibody showed induction of RELA and STAT5 DNA-binding segments both in naïve cells treated with a high concentration of carboplatin as well as in carboplatin-resistant cells.
Conclusions: Proteomic analysis identified RELA and STAT5 as two major proteins associated with carboplatin resistance in ovarian tumors. Our results further showed that NF-kappaB and STAT5 inhibitor could sensitize carboplatin-resistant cells and suggest that such inhibitors can be used to benefit patients with carboplatin-resistant recurrent ovarian cancer.

Front Biosci. 2008 May 01;13:6237-54. (PMID: 18508657)
Blood. 2008 Jun 15;111(12):5663-71. (PMID: 17984313)
CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49. (PMID: 19474385)
Mol Cell Biol. 2000 Apr;20(8):2687-95. (PMID: 10733571)
Cancer Res. 2006 Oct 15;66(20):9948-56. (PMID: 17047057)
Expert Rev Proteomics. 2005 Oct;2(5):659-67. (PMID: 16209646)
Blood. 2000 Sep 15;96(6):2269-76. (PMID: 10979976)
Annu Rev Immunol. 2000;18:621-63. (PMID: 10837071)
Clin Cancer Res. 2004 Nov 15;10(22):7645-54. (PMID: 15569997)
Cancer Res. 2008 Jan 1;68(1):236-48. (PMID: 18172316)
Clin Cancer Res. 2007 Dec 1;13(23):7191-8. (PMID: 18056200)
Proc Natl Acad Sci U S A. 2006 Dec 5;103(49):18739-44. (PMID: 17130457)
J Biol Chem. 2004 May 28;279(22):23477-85. (PMID: 15026414)
Clin Cancer Res. 2007 Nov 15;13(22 Pt 1):6842-9. (PMID: 17982121)
J Biol Chem. 2003 Jan 17;278(3):1450-6. (PMID: 12403772)
Cancer Res. 2009 Feb 15;69(4):1407-15. (PMID: 19190325)
Oncogene. 1999 Jul 22;18(29):4191-9. (PMID: 10435632)
Gynecol Oncol. 2005 Feb;96(2):287-95. (PMID: 15661210)
Cancer Res. 2006 Jul 15;66(14):7007-15. (PMID: 16849545)
Oncogene. 2002 Sep 19;21(42):6510-9. (PMID: 12226754)
J Exp Med. 2003 Jul 7;198(1):79-89. (PMID: 12835478)
Gynecol Oncol. 2007 Apr;105(1):31-44. (PMID: 17275076)
J Clin Oncol. 2005 Sep 1;23(25):5943-9. (PMID: 16135465)
Annu Rev Pathol. 2009;4:287-313. (PMID: 18842102)
Mol Oncol. 2008 Aug;2(2):153-60. (PMID: 19383334)
Proc Natl Acad Sci U S A. 2005 Sep 27;102(39):14004-9. (PMID: 16172393)
Neoplasia. 2009 Jun;11(6):605-14, 1 p following 614. (PMID: 19484149)
Expert Rev Proteomics. 2009 Apr;6(2):123-34. (PMID: 19385940)
Oncogene. 2002 Apr 25;21(18):2846-53. (PMID: 11973644)
Mol Cancer Ther. 2007 Apr;6(4):1400-5. (PMID: 17431118)
Cell Cycle. 2009 Jan 1;8(1):158-66. (PMID: 19158483)
BMC Med Genomics. 2008 Nov 28;1:59. (PMID: 19038057)
Oncogene. 2009 May 7;28(18):1941-8. (PMID: 19305429)

R42 CA122715 United States CA NCI NIH HHS; R01 CA 103937 United States CA NCI NIH HHS; R41 CA122715 United States CA NCI NIH HHS; R01 CA129080 United States CA NCI NIH HHS; GM073723 United States GM NIGMS NIH HHS; CA 122715 United States CA NCI NIH HHS; R01 CA103937 United States CA NCI NIH HHS; R01 GM073723 United States GM NIGMS NIH HHS; R01 CA 129080 United States CA NCI NIH HHS

0 (Antineoplastic Agents)
0 (Neoplasm Proteins)
0 (RELA protein, human)
0 (STAT5 Transcription Factor)
0 (Transcription Factor RelA)
BG3F62OND5 (Carboplatin)

Date Created: 20100630 Date Completed: 20110113 Latest Revision: 20211020

20250114

PMC2887843

10.1371/journal.pone.0011198

20585448